Form 4: Apogee Therapeutics Director Receives Stock Option Grant

Director Lisa Bollinger was granted 7,657 stock options in Apogee Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Lisa Bollinger received a grant of 7,657 stock options on June 9, 2026.
• The options have an exercise price of $85.00 per share.
• The options are set to expire on June 9, 2036.
• The grant is subject to a one-year vesting schedule, contingent upon continued service to the company.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is contingent upon continued service, creating potential turnover risk if the director departs before the one-year anniversary.

Future Outlook

The options vest on the one-year anniversary of the grant date, June 9, 2027, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure alignment between board members and shareholders.

Comparison to Industry Standards

• The use of time-based vesting for director equity is consistent with standard practices for mid-cap biotechnology firms.
• The 10-year term for options is a standard industry benchmark for executive and director compensation packages.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the 7,657 stock options on June 9, 2027.

Key Dates

Keywords

Apogee Therapeutics, APGE, Form 4, Insider Trading, Stock Options, Director Compensation